Investors should monitor enrollment progress and safety signals ahead of the late 2026/early 2027 data readout. A successful Phase 1 could de-risk the program and expand Septerna’s valuation premium, especially if SEP-479 demonstrates pharmacodynamic activity and differentiates from injectable PTH therapies.
SEPN drugs
SEPN drug pipeline →How the stock moved after the report
⚠ Clustered BULLISH VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 13 $23.34entry
- T+1 · 7mo ago +3.38%α +2.17% · $24.13
- T+5 · 7mo ago +15.08%α +11.79% · $26.86
- T+20 · 6mo ago +0.99%α −6.74% · $23.57
- T+60 · 4mo ago +55.96%α +47.03% · $36.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Septerna announced the dosing of the first participants in its Phase 1 trial of SEP-479, an oral small molecule PTH1R agonist for hypoparathyroidism. Clinical data is expected in late 2026 or early 2027. This marks a key milestone in advancing a potential first-in-class oral therapy for a rare endocrine disorder.
Key Facts
- Septerna has initiated dosing in the Phase 1 clinical trial of SEP-479 for hypoparathyroidism.
- The trial is a single- and multiple-ascending dose study in healthy volunteers, evaluating safety, tolerability, PK, and PD.
- Up to 150 participants will be enrolled; data readout expected in late 2026 or early 2027.
- SEP-479 is a potent oral small molecule agonist targeting the PTH1R receptor, aiming to provide once-daily dosing.
- Preclinical data showed normalization of serum calcium and favorable tolerability in GLP toxicology studies.
Financial Impact
No immediate financial impact; long-term commercial potential hinges on clinical success. Hypoparathyroidism market remains underserved, with current treatments involving daily injections or high-dose supplements.
Risk Factors
- Phase 1 may reveal unexpected safety, PK, or PD findings that could halt development.
- Preclinical results may not translate to humans, particularly in disease-modifying effects.
- Timing delays in trial completion or data readout could dampen investor enthusiasm.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3272435 |
Track record
25 reports on SEPN
6 of 6 bullish or bearish reports moved the stock their way by T+5. Best: +14.69% at T+20 after the Aug 12, 2026 report. 7 of 7 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 2/10 Entry price pending
- Nov 16, 2026today 144 Neutral 2/10 Entry price pending
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $42.60 Now $41.67 −2.18% settles Nov 20
- Nov 12, 20264d ago 144 Neutral 3/10 Entry $41.86 Now $41.67 −0.45% settles Nov 19
- Nov 9, 20267d ago Press Release Bearish 5/10 Entry $52.34 Now $41.67 +20.39% settles Nov 17
- Nov 4, 202612d ago 8-K Neutral 3/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
- Nov 4, 202612d ago Press Release Neutral 4/10 Entry $47.88 to $48.56 Now $41.67 −12.97% ▲ +1.42% +2.33% vs SPY
- Sep 10, 20269w ago Press Release Neutral 2/10 Entry $38.51 to $38.69 Now $41.67 +8.21% ▲ +0.47% +0.69% vs SPY
- Sep 3, 202610w ago 3 Neutral 2/10 Entry $36.75 to $39.55 Now $41.67 +13.39% ▲ +7.62% +8.83% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers